Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab

Jamie A Keen; Tatiana Correa; Chau Pham; Alexander D Claussen; Marlan R Hansen; Keith D Carter; Erin M Shriver

doi:10.1016/j.ophtha.2023.08.001

Back

Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab

Journal article

Open access

Peer reviewed

Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab

Jamie A Keen, Tatiana Correa, Chau Pham, Alexander D Claussen, Marlan R Hansen, Keith D Carter and Erin M Shriver

Ophthalmology (Rochester, Minn.), Vol.131(1), pp.30-36

01/2024

DOI: 10.1016/j.ophtha.2023.08.001

PMID: 37567417

Files and links (1)

url

https://doi.org/10.1016/j.ophtha.2023.08.001View

Published (Version of record) Open Access

Abstract

Purpose To better characterize the frequency and patterns of hearing dysfunction in patients who have received teprotumumab to treat thyroid eye disease. Design Non-comparative case series. Subjects Patients who underwent audiology testing before and after completion of teprotumumab infusions. Methods A review of patients who underwent audiology testing before and after completion of teprotumumab infusions. Additional mid-treatment audiogram testing was included when available. Hearing function was analyzed using audiogram data measuring threshold hearing levels at specific frequencies. Basic demographic data as well as information regarding otologic symptoms were also obtained and analyzed. Main Outcome Measures Hearing loss demonstrated by a significant change in decibel hearing thresholds or that meets criteria for ototoxicity. Results Twenty-two patients (44 ears) were included in the study, with baseline and most recent post-treatment audiology testing ranging from 84 days before to 496 days after treatment. Fifteen patients (30 ears) also had mid-treatment testing starting after the second infusion up until the day of but before the eighth infusion. Post-treatment hearing loss met criteria for ototoxicity in 17 of the 44 ears (38.6%) with 11 of the 22 patients (50.0%) meeting criteria in at least one ear. The pure tone average (PTA) decibel hearing levels (dB HL) across all 44 ears demonstrated post-treatment hearing loss (p=0.0029) specifically at high (p=0.0008) and mid-frequencies (p=0.0042), but not at low frequencies (p=0.8344). Patients who were older were also more likely to experience post-treatment hearing loss (p=0.0048). Conclusions Audiometric data demonstrates that teprotumumab influences hearing function, most significantly at higher frequencies and in older patients. Audiometric testing is critical for counseling patients regarding teprotumumab treatment. A protocol for monitoring hearing during treatment is needed to detect and manage hearing changes associated with teprotumumab.

Audiology

thyroid eye disease

hearing loss

ototoxicity

teprotumumab

Details

Title: Subtitle: Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab
Creators: Jamie A Keen - University of Iowa Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, USA
Tatiana Correa - University of Iowa
Chau Pham - University of Iowa
Alexander D Claussen - University of Iowa
Marlan R Hansen - University of Iowa
Keith D Carter - University of Iowa
Erin M Shriver
Resource Type: Journal article
Publication Details: Ophthalmology (Rochester, Minn.), Vol.131(1), pp.30-36
DOI: 10.1016/j.ophtha.2023.08.001
PMID: 37567417
NLM abbreviation: Ophthalmology
ISSN: 0161-6420
eISSN: 1549-4713
Grant note: DOI: 10.13039/100004374, name: Medtronic; DOI: 10.13039/501100018857, name: MED-EL Medical Electronics; DOI: 10.13039/100001818, name: Research to Prevent Blindness
Language: English
Electronic publication date: 08/09/2023
Date published: 01/2024
Academic Unit: Molecular Physiology and Biophysics; Neurosurgery; Otolaryngology; Ophthalmology and Visual Sciences
Record Identifier: 9984455616402771

Metrics

13 Record Views

See more details